ICON launches FIRECREST Pre-Screen

ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of FIRECREST Pre-Screen, an innovative digital solution that increases the efficiency and quality of initial patient eligibility assessments.

FIRECREST Pre-Screen provides a more robust solution for site personnel to identify potentially eligible patients which can lead to improved enrolment rates and reduced costs by preventing ineligible patients from progressing to the full screening stage. 

ICON has developed FIRECREST Pre-Screen to address the ongoing industry challenge of patient recruitment, which can represent more than 30% of total study costs. ICON clinical trial experts work with study clinicians to identify suitable eligibility criteria for pre-screen assessments, and convert the criteria into a series of easy to understand questions that are available to study personnel via the FIRECREST Site Portal.

Each assessment is stored on the portal and study teams can access aggregated data to view real-time pre-screen activity.  This increased transparency provides early insight into study criteria that may be impacting patient recruitment.

“FIRECREST Pre-Screen supports site staff in identifying eligible patients more efficiently while saving time and minimising site burden and associated costs for the sponsor,” commented Mark Connolly, VP FIRECREST at ICON.  “It also minimises burden on patients by more precisely identifying appropriate patients for full screening.”

The FIRECREST Site Portal is a single sign-on, central hub for digital solutions, including ICON’s award winning GCP and Protocol Overview training modules, Visit By Visit Guide and Trial Drive for the distribution and tracking of study critical documents to sites. It also enables the hosting of third party and sponsor training content with learning management and compliance features.

To learn more about ICON’s FIRECREST digital solutions, visit www.iconplc.com/innovation/firecrest

About ICON plc

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,100 employees..

ICON Press Office Enquiries

Weber Shandwick
Email: LDNWSWICONClinical@corp.ipgnetwork.com

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.